Literature DB >> 19158361

Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction.

Shuso Takeda1, Yuji Ishii, Megumi Iwanaga, Arief Nurrochmad, Yuji Ito, Peter I Mackenzie, Kiyoshi Nagata, Yasushi Yamazoe, Kazuta Oguri, Hideyuki Yamada.   

Abstract

We have reported that the protein-protein interaction between UDP-glucuronosyltransferase (UGT) 2B7 and cytochrome P450 3A4 (CYP3A4) alters UGT2B7 function. However, the domain(s) involved in the interaction are largely unknown. To address this issue, we examined in more detail the CYP3A4-UGT2B7 association by means of immunoprecipitation, overlay assay, and cross-linking involving 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide. Purified CYP3A4 or glutathione transferase (GST)-tagged CYP3A4 was cross-linked to UGT2B7 in solubilized baculosomes. The formation of the cross-linked complex was detected by immunoblotting using both antibodies against CYP3A4 and UGTs. Although the GST-tagged CYP3A4 containing the region ranging from Tyr25 to Ala503 was cross-linked to UGT2B7, the same did not occur when another construct containing Met145 to His267 was used. This observation was consistent with the result of the overlay assay indicating that CYP3A4 lacking the N-terminal hydrophobic segment retains the ability to associate with UGT2B7, whereas the Met145-to-His267 region loses this capacity. Although the Met145-to-His267 peptide was recognized by one anti-CYP3A4 antibody that has the ability to coimmunoprecipitate UGT2B7, it was not recognized by another antibody incapable of coimmunoprecipitating UGT2B7. The epitope of the latter antibody was mapped to the Leu331-to-Lys342 region, which is located on the J-helix of CYP3A4. Taken together, the results obtained suggest that 1) CYP3A4 and UGT2B7 are a pair of enzymes in proximity to each other and 2) either the Leu331-to-Lys342 domain or the surrounding region plays a role in the interaction with UGT2B7, whereas the hydrophobic Met145-to-His267 region does not contribute to this interaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158361     DOI: 10.1124/mol.108.052001

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions.

Authors:  Diane Ramsden; Donald J Tweedie; Tom S Chan; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2014-08-25       Impact factor: 3.922

2.  Cannabidiol-2',6'-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro.

Authors:  Shuso Takeda; Akari Hirayama; Shino Urata; Nobutaka Mano; Keiko Fukagawa; Midori Imamura; Ayumi Irii; Satomi Kitajima; Tomoko Masuyama; Mai Nomiyama; Sachiko Tatei; Saari Tomita; Taichi Kudo; Momoko Noguchi; Yasuhiro Yamaguchi; Yoshiko Okamoto; Toshiaki Amamoto; Yoshifumi Fukunishi; Kazuhito Watanabe; Curtis John Omiecinski; Hironori Aramaki
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

3.  Δ(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ).

Authors:  Shuso Takeda; Kazutaka Yoshida; Hajime Nishimura; Mari Harada; Shunsuke Okajima; Hiroko Miyoshi; Yoshiko Okamoto; Toshiaki Amamoto; Kazuhito Watanabe; Curtis J Omiecinski; Hironori Aramaki
Journal:  Chem Res Toxicol       Date:  2013-06-11       Impact factor: 3.739

4.  (-)-Xanthatin up-regulation of the GADD45γ tumor suppressor gene in MDA-MB-231 breast cancer cells: role of topoisomerase IIα inhibition and reactive oxygen species.

Authors:  Shuso Takeda; Momoko Noguchi; Kazumasa Matsuo; Yasuhiro Yamaguchi; Taichi Kudo; Hajime Nishimura; Yoshiko Okamoto; Toshiaki Amamoto; Mitsuru Shindo; Curtis J Omiecinski; Hironori Aramaki
Journal:  Toxicology       Date:  2013-01-08       Impact factor: 4.221

5.  Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.

Authors:  Shuso Takeda; Shunsuke Okajima; Hiroko Miyoshi; Kazutaka Yoshida; Yoshiko Okamoto; Tomoko Okada; Toshiaki Amamoto; Kazuhito Watanabe; Curtis J Omiecinski; Hironori Aramaki
Journal:  Toxicol Lett       Date:  2012-09-08       Impact factor: 4.372

6.  Convergent evolution in biosynthesis of cyanogenic defence compounds in plants and insects.

Authors:  Niels Bjerg Jensen; Mika Zagrobelny; Karin Hjernø; Carl Erik Olsen; Jens Houghton-Larsen; Jonas Borch; Birger Lindberg Møller; Søren Bak
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

7.  Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome.

Authors:  Ryoichi Fujiwara; Tomoo Itoh
Journal:  Pharmacol Res Perspect       Date:  2014-07-02

8.  Introduction of an N-Glycosylation Site into UDP-Glucuronosyltransferase 2B3 Alters Its Sensitivity to Cytochrome P450 3A1-Dependent Modulation.

Authors:  Tatsuro Nakamura; Naho Yamaguchi; Yuu Miyauchi; Tomoki Takeda; Yasushi Yamazoe; Kiyoshi Nagata; Peter I Mackenzie; Hideyuki Yamada; Yuji Ishii
Journal:  Front Pharmacol       Date:  2016-11-14       Impact factor: 5.810

Review 9.  Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases.

Authors:  Ryoichi Fujiwara; Tsuyoshi Yokoi; Miki Nakajima
Journal:  Front Pharmacol       Date:  2016-10-24       Impact factor: 5.810

10.  UDP-Glucuronosyltransferase (UGT)-mediated attenuations of cytochrome P450 3A4 activity: UGT isoform-dependent mechanism of suppression.

Authors:  Yuu Miyauchi; Yoshitaka Tanaka; Kiyoshi Nagata; Yasushi Yamazoe; Peter I Mackenzie; Hideyuki Yamada; Yuji Ishii
Journal:  Br J Pharmacol       Date:  2020-01-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.